Celltrion's Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia
- Herzuma is first biosimilar approved in Australia for the treatment of early breast cancer- locally advanced or metastatic or advance gastric cancer
- Including Herzuma Celltrion has three biosimilar for Australia- Remsima for autoimmune disease- Truxima for blood cancer approved in Aug 2015 and April 2018 respectively
- Celltrion plans to launch Herzuma in Australia after discussing the situation of local market with its subsidiary Celltrion Healthcare
/ article | Ref: Celltrion | Image: Celltrion
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].